Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart surgery showdown: which procedure saves more lives in weak hearts?

NCT ID NCT07269366

Disease control Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two common heart procedures—bypass surgery (CABG) and stenting (PCI)—in 358 people with weak hearts (ejection fraction 40% or less) and multiple blocked arteries. The goal is to see which approach leads to better survival, fewer heart attacks or strokes, and improved quality of life over 4 years. Participants must have chest pain or a recent heart-related hospitalization.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 358 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

May 2034

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * LVEF≤ 40% * Angina pectoris, CCS≥2 and/or hospitalization for ACS or heart failure within 1 year prior to randomization * Multivessel CAD (2-3 vessel-disease with coronary lesions \>70% and involvement of proximal LAD, and/or LM stenosis of \>50%). Target vessels are determined by the local Heart Time * Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team * Written informed consent Exclusion Criteria: * ACS \< 48 hours before randomization * Valvular/structural heart disease requiring intervention * Contra-indications to DAPT * Non-cardiac condition with life expectancy \< 1 year * Previous CABG * Decompensated HF at the time of inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CABG are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder heart failure left ventricular failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CABG Cabg in low ef Coronary artery disease Coronary artery disease (CAD) Heart failure Multivessel coronary artery disease PCI Revascularization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Medical Center Groningen

    RECRUITING

    Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.